JIANMIN PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.81 CNY | -2.26% |
|
+5.80% | -5.27% |
| 19/04 | Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 16/04 | Jianmin Pharma Gets Nod to Market Asthma Drug | MT |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- The company returns high margins, thereby supporting business profitability.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -5.27% | 133.07Cr | - | ||
| +32.36% | 71TCr | C+ | ||
| +30.77% | 60TCr | B | ||
| -1.60% | 37TCr | C+ | ||
| +20.07% | 33TCr | B- | ||
| +6.04% | 29TCr | C+ | ||
| +14.77% | 24TCr | B+ | ||
| +9.13% | 21TCr | B- | ||
| -3.97% | 20TCr | A+ | ||
| +9.27% | 17TCr | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600976 Stock
- Ratings Jianmin Pharmaceutical Group Co.,Ltd.